International Stem
Cell Corp., a California-based biotechnology company focused on developing
novel stem cell-based therapies and biomedical products, announced today that
Dr. Ruslan Semechkin, ISCO’s Chief Scientific Officer, will present data from
its pre-clinical primate studies of Parkinson’s disease at the 66th American
Academy of Neurology Annual Meeting in Philadelphia. The meeting is scheduled
for Tuesday, April 29, 2014, at 1:00 p.m. EST. The topic is ‘Movement
Disorders’ and the Session title is ‘Parkinson’s disease: Preclinical and
Clinical Therapeutics.’
The American Academy
of Neurology Annual Meeting is known to be the world’s largest gathering of
neurologists. The American Academy of Neurology is an association of more than
27,000 neurologists and neuroscience professionals who are dedicated to
promoting the highest quality patient-centered neurologic care. Neurologist’s
are doctors with specialized training in diagnosing, treating and managing
disorders of the brain and nervous system such as Alzheimer’s disease, stroke,
migraine, multiple sclerosis, concussion, Parkinson’s disease, and epilepsy.
ISCO’s work centers
on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and
the development and commercialization of cell-based research and cosmetic
products. The company’s core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes (eggs)
thereby avoiding ethical issues associated with the use or destruction of
viable human embryos. Most notably, ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of therapeutic
cells for hundreds of millions of people of different genders, ages, and racial
backgrounds with minimal immune rejection after transplantation. hpSCs provide
the potential to create the first true stem cell bank, UniStemCell™.
International Stem Cell also produces and markets specialized cells and growth
media for therapeutic research around the world through its subsidiary Lifeline
Cell Technology, and stem cell-based skin care products through its subsidiary
Lifeline Skin Care.
The Parkinson’s
Disease Foundation notes an estimated seven to 10 million people worldwide live
with Parkinson’s disease, with as many as one million in the United States
alone, more than the combined total of people diagnosed with multiple
sclerosis, muscular distrophy, and Lou Gehrig’s disease. The total cost of
Parkinson’s disease is estimated to be nearly $25 billion per year in the
United States alone.
More information is
available at www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
International Stem
Cell Corp., a California-based biotechnology company focused on developing
novel stem cell-based therapies and biomedical products, announced today that
Dr. Ruslan Semechkin, ISCO’s Chief Scientific Officer, will present data from
its pre-clinical primate studies of Parkinson’s disease at the 66th American
Academy of Neurology Annual Meeting in Philadelphia. The meeting is scheduled
for Tuesday, April 29, 2014, at 1:00 p.m. EST. The topic is ‘Movement
Disorders’ and the Session title is ‘Parkinson’s disease: Preclinical and
Clinical Therapeutics.’
The American Academy
of Neurology Annual Meeting is known to be the world’s largest gathering of
neurologists. The American Academy of Neurology is an association of more than
27,000 neurologists and neuroscience professionals who are dedicated to
promoting the highest quality patient-centered neurologic care. Neurologist’s
are doctors with specialized training in diagnosing, treating and managing
disorders of the brain and nervous system such as Alzheimer’s disease, stroke,
migraine, multiple sclerosis, concussion, Parkinson’s disease, and epilepsy.
ISCO’s work centers
on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and
the development and commercialization of cell-based research and cosmetic
products. The company’s core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes (eggs)
thereby avoiding ethical issues associated with the use or destruction of
viable human embryos. Most notably, ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of therapeutic
cells for hundreds of millions of people of different genders, ages, and racial
backgrounds with minimal immune rejection after transplantation. hpSCs provide
the potential to create the first true stem cell bank, UniStemCell™.
International Stem Cell also produces and markets specialized cells and growth
media for therapeutic research around the world through its subsidiary Lifeline
Cell Technology, and stem cell-based skin care products through its subsidiary
Lifeline Skin Care.
The Parkinson’s
Disease Foundation notes an estimated seven to 10 million people worldwide live
with Parkinson’s disease, with as many as one million in the United States
alone, more than the combined total of people diagnosed with multiple
sclerosis, muscular distrophy, and Lou Gehrig’s disease. The total cost of
Parkinson’s disease is estimated to be nearly $25 billion per year in the
United States alone.
More information is
available at www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment